Paul Wang

Paul Wang, MD is a developmental-behavioral pediatrician affiliated with Yale School of Medicine and the Simons Foundation. His career spans academia, pharma, biotech, and non-profit sectors with a focus on drug development for autism and genetic disorders like Fragile X syndrome and 16p11.2 deletion syndrome. He leads clinical trial design, outcome measure validation, and biomarker strategy for autism drug development. He chairs the federally-appointed Interagency Autism Coordinating Committee and holds leadership roles in professional organizations like the American Academy of Pediatrics.

Education: MD from Yale School of Medicine (1986), AB Harvard College (1982). Training includes residency at University of Michigan, research fellowships at Salk Institute, and clinical fellowship at Children's Hospital of Philadelphia.

Research interests center on neurodevelopmental disorders, clinical trial methodologies, and translational research. His work emphasizes bridging basic science and clinical applications, particularly for rare genetic conditions. Key contributions include pioneering trials for Fragile X syndrome and developing standardized adaptive behavior assessment tools.

Publications (2010–2021) focus on drug development frameworks, clinical trial strategies, and behavioral outcomes in autism and genetic syndromes. He collaborates with institutions globally on neurodevelopmental frameworks for drug discovery.

Professional service includes roles on the American Board of Pediatrics and leadership in autism advocacy initiatives. His work aims to accelerate therapies through interdisciplinary collaboration and rigorous trial design.